Now Is the Time to Remove Barriers to AID Treatment for Those With Detectable C-Peptide

In an automated insulin delivery (AID) system, data from an individual’s continuous glucose monitor (CGM) are fed into a mathematical algorithm that uses their glucose data to modulate insulin delivery via an insulin pump. AID systems have been demonstrated to provide protection against both low and high glucose levels in type 1 diabetes (1–5) and are also associated with improvements in quality of life (6–7). Assessment of clinical effectiveness and cost-effectiveness (8) by bodies that can influence policy is a key element of ensuring access to treatments for those who stand to benefit. For example, in England and Wales, assessments are undertaken by the National Institute for Health and Care Excellence (NICE). Their publication of a supportive assessment (Technology Appraisal 943) (9) is now driving the national provision of the use of AID systems in people with type 1 diabetes who meet clearly defined prespecified criteria. This is one example of AID systems becoming the standard of care for people with type 1 diabetes internationally.